In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Lisata Therapeutics (LSTA – Research Report), with a price target of $15.00. The company’s shares closed yesterday at $1.99.
Pantginis covers the Healthcare sector, focusing on stocks such as BioCardia, Krystal Biotech, and Panbela Therapeutics. According to TipRanks, Pantginis has an average return of -9.0% and a 30.80% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lisata Therapeutics with a $15.00 average price target.
See the top stocks recommended by analysts >>
Based on Lisata Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $4.03 million. In comparison, last year the company had a GAAP net loss of $6.63 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Read More on LSTA:
- Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors
- Lisata Therapeutics announces first patient treated in BOLSTER trial
- Lisata Therapeutics says IDSMC recommends study continuation of ASCEND trial
- Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- Lisata Therapeutics announces FDA ODD granted to LSTA1
